Notably, ATM-negative patients treated with olaparib showed significantly improved remission rates compared to ATM-negative patients treated with paclitaxel alone (ORR 4.24, p = .0309), so PARPis may still be effective in selecting the correct biomarker for GC [103]. Here, ATM is linked to gastric cancer.